Trius Therapeutics (TSRX) to Present Experimental Antibiotic Study Results at ECCMID Meeting
4/23/2013 11:23:46 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAN DIEGO, April 23, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the results of a large, late-stage human study, called ESTABLISH 2, and multiple other clinical studies from its experimental antibiotic, tedizolid phosphate (TR-701), will be presented in poster and oral presentations at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting in Berlin from April 27-30. A total of three tedizolid-related posters and one oral presentation have been accepted for presentation, including clinical and safety results.
Help employers find you! Check out all the jobs and post your resume.